Vivek B. Shenoy, PhD, MBA
Dr. Shenoy took over as CEO of Renovo in June 2016. He succeeded the founding CEO Dr. Satish Medicetty, and joined a strong team and operational structure that has contributed to Renovo’s progress and accomplishments since its inception. Dr. Shenoy brings over 25 years of combined experience in research, drug development and commercial roles. He has held several senior positions at AstraZeneca, Incyte Corporation and Biocon Limited, bringing robust global industry experience to Renovo. He started his career in Mumbai, India, and obtained his Bachelor’s and Master’s degrees from the University of Bombay (Mumbai). He earned a PhD in Molecular Biology from the University of Florida (UF). Following his PhD, he joined the department of Pediatrics, and helped set up the Neonatal and Biochemical Research Laboratory at UF, and trained several MD fellows, Post-graduate and undergraduate research associates. He chose to pursue an MBA in International Business and Entrepreneurship and worked at a start-up biotech venture focusing on nucleic acid diagnostics, before joining AstraZeneca, where he worked for nearly 12 years in various roles in Sales, Product Development, Product Management and BD&L. Dr. Shenoy then took an opportunity to head the Novel Programs pipeline for Biocon Limited in Bangalore, India. Most recently he has been involved in several BD&L deals in the biopharmaceutical industry after his return to the US.
Bruce Trapp, PhD
Founder, Chairman of SAB and Chief Scientific Officer
Dr. Bruce D. Trapp is Chairman of the Department of Neurosciences at the Lerner Research Institute, Cleveland Clinic and Professor of Neurosciences at Case Western Reserve University. Dr. Trapp received his Ph.D. from Loyola University Stritch School of Medicine in Chicago, IL. He received postdoctoral training at the National Institutes of Health (NIH), Bethesda, MD and then was appointed Assistant and subsequently Associate Professor of Neurology at the Johns Hopkins University School of Medicine in Baltimore. He joined the Cleveland Clinic as Chairman of the Department of Neurosciences in 1994. He is the recipient of the Jordi Folch-Pi Award from the American Society of Neurochemistry, The Weil Award from the American Association of Neuropathologists, the Harry Weaver Neuroscience Scholar Award from the National Multiple Sclerosis Society (NMSS), the Jacob Javits Award in Neuroscience from the National Institute of Neurological Disorders and Stroke, the John Dystel Prize for MS Research from the American Academy of Neurology and the National Multiple Sclerosis Society, the Scientific Achievement Award in Basic Science and the Award for Excellence in Science from the Cleveland Clinic and Dr Trapp is a Fellow of the AAAS. Dr. Trapp’s research investigates the cause of neurological disability in multiple sclerosis patients, cellular mechanism of brain repair in neurodegenerative diseases, and the molecular biology of myelination in the central and peripheral nervous systems. He is internationally known for his work on mechanisms of neurodegeneration and repair in multiple sclerosis and has published over 185 peer-reviewed articles and over 30 book chapters. Dr Trapp sits on the advisory board of major biotech companies, the National Institutes of Health and the National Multiple Sclerosis Society and he is active in organizing national and international conferences related to Neurodegenerative diseases.
Doug Morton, PhD
Doug Morton is presently a consultant in the life sciences, working with a variety of for-profit and non-profit organizations. From 2003-2006, he was CEO, Southwest Michigan Innovation Center
, an incubator/accelerator located in Kalamazoo, MI that provides wet-laboratory space, access to venture funding and business services to emerging companies in the life sciences arena. Since 2006, he has continued his involvement with the Center as a member of its Managing Directors group. Doug spent the majority of his career in the pharmaceutical industry, joining the Upjohn Company as a research scientist in 1973. He remained with the surviving entity through Upjohn’s subsequent mergers until 2003 when he worked as Group Vice President, Technology Acquisitions & Operations for Discovery Research in Pharmacia Corporation. In this position, he was responsible for technology acquisition and operations for worldwide Discovery Research throughout Pharmacia. Doug holds an A.B. degree (chemistry) from Kenyon College and a Ph.D. degree in Organic Chemistry from Columbia University. He completed postdoctoral studies in organic chemistry at Stanford University. Doug has served on the Board of Directors of TissueInformatics, Inc. from May 2003 until the closing of Paradigm Genetics’ acquisition of the company in March 2004. He served as a member of the Board of Directors of Icoria, Inc. (formerly Paradigm Genetics, Inc.) since March 2004 until the acquisition of the Company by Clinical Data, Inc. in December 2005. He also served as Interim CEO of Icoria since April 2005 until the close of the acquisition with Clinical Data. Doug is currently a member of the Industrial Advisory Board of Cleveland Clinic Foundation Innovations,a member of the Scientific Advisory Board and Management Committee of the Southwest Michigan First Life Science Fund, and chairman of the Scientific Advisory Boards of Hopen Therapeutics and Metabolic Solutions Development Company. Doug is also a board member of NephRx Corporation, TCH Pharmaceuticals, Inc., and Tolera Therapeutics, Inc.
Tina Rogers, PhD, MBA, DABT
Tina Rogers is currently the Vice President at SNBL USA. Dr. Rogers has a unique combination of scientific and business experience. With more than 20 years of experience in the CRO field, she has held key leadership positions, most recently as Executive Vice President and Director of Research at MPI Research. Dr. Rogers received a PhD from the Medical University of South Carolina in molecular and cellular biology and pathobiology, and completed postdoctoral fellowships at Harvard Medical School and Tufts University School of Medicine. She serves on the MBA Advisory Board at the Auburn University School of Business and is a member of the Gerson Lehman Group Healthcare Council.